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INTRODUCTION
Resistant hypertension (HTN) is defined as either the failure 
to achieve the target blood pressure (BP; <140/90) with three 
antihypertensive drugs of different classes, including diuret-
ics, or the achievement of BP by using four or more antihyper-
tensive drugs.1 It is associated with a significant elevation of 
cardiovascular risk.2-4 Therefore, early recognition and rigor-
ous management are necessary to reduce cardiovascular mor-
tality.5 The prevalence of resistant HTN has been reported to be 
as high as 30% in hypertensive patients.4 There are many causes 
of resistant HTN, including high sodium-containing diets, alco-
hol, non-adherence to drug treatments, inadequate medications, 
obesity, and secondary HTN.6 Among the causes of secondary 
HTN, obstructive sleep apnea (OSA) is strongly associated with 
resistant HTN.7 Surprisingly, the prevalence of OSA in resis-
tant hypertensive patients ranges from 64%8 to 83%,9 which is 
significantly higher than its prevalence (4%) in the general pop-
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Purpose: Resistant hypertension (HTN) occurs in 15–20% of treated hypertensive patients, and 70–80% of resistant hypertensive 
patients have obstructive sleep apnea (OSA). The characteristics of resistant HTN that predispose patients to OSA have not been 
reported. Therefore, we aimed to determine the clinical, laboratory, and polysomnographic features of resistant HTN that are sig-
nificantly associated with OSA. 
Materials and Methods: Hypertensive patients (n=475) who underwent portable polysomnography were enrolled. The patients 
were categorized into controlled (n=410) and resistant HTN (n=65) groups. The risk factors for the occurrence of OSA in controlled 
and resistant hypertensive patients were compared, and independent risk factors that are associated with OSA were analyzed. 
Results: Out of 475 patients, 359 (75.6%) were diagnosed with OSA. The prevalence of OSA in resistant HTN was 87.7%, which 
was significantly higher than that in controlled HTN (73.7%). Age, body mass index, neck circumference, waist circumference, 
and hip circumference were significantly higher in OSA. However, stepwise multivariate analyses revealed that resistant HTN was 
not an independent risk factor of OSA. 
Conclusion: The higher prevalence and severity of OSA in resistant HTN may be due to the association of risk factors that are 
common to both conditions.
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ulation.10 
OSA is characterized by the partial or complete collapse of 
the upper airway during sleep, and it is diagnosed when the 
apnea-hypopnea index (AHI), as detected by polysomnogra-
phy (PSG), is greater than 5. OSA affects 2–4% of adults and is 
associated with increased cardiovascular risks and mortality.11 
It is very common in hypertensive patients, and the prevalence 
has been reported to be as high as 56%.12,13 Resistant HTN and 
OSA are commonly associated with various physiological con-
ditions, such as hyperaldosteronism, increased sympathetic 
activity, endothelin- and hypoxia-mediated vasoconstriction, 
and obesity.14 Furthermore, BP control is critical for reducing 
cardiovascular morbidity and mortality,15 and the treatment of 
OSA with continuous positive airway pressure (CPAP) modestly 
diminishes BP in patients with various types of HTN,16 includ-
ing resistant HTN.17 The modest effect of CPAP on BP reduction 
in resistant hypertensive patients suggests that the high preva-
lence of OSA in these patients may not entirely be explained by 
sleep apnea which exacerbates blood pressure elevation, but 
also be due to common associations with risk factors. There-
fore, OSA and resistant HTN do not appear be causally related. 
In this study, we aimed to determine the clinical, laboratory, 
and polysomnographic features of resistant HTN that are sig-
nificantly associated with OSA. Also, we determined the asso-
ciation of resistant HTN with OSA after controlling for risk fac-
tors that are related to both conditions.   
MATERIALS AND METHODS
Study population
This retrospective study was approved by the Institutional Re-
view Board (IRB) at Yonsei University College of Medicine (IRB 
No. 4-2014-0132). We enrolled hypertensive patients who vis-
ited the Cardiology Department at Yonsei University College 
of Medicine between 2010 and 2013 who completed the PSG 
procedure, sleep questionnaires, and basal blood tests. PSG was 
performed using Embletta X100 (Natus Embla Systems LLC, 
Ontario, Canada),18 which is a type 2 full-unattended portable 
system by the American Academy of Sleep Medicine.19 This type 
2 portable monitor incorporates a minimum of seven channels, 
including two electroencephalography (EEG) channels. This al-
lows for the AHI to be accurately calculated and is an improve-
ment over the rough estimates that are obtained by type 3 or 4 
portable systems.20 The inter- [95% confidence interval (CI), 
0.993–0.999; p<0.001] and intra-class correlation coefficients 
(95% CI, 0.993–0.999; p<0.001) for the inter-observer reliability 
of the AHI were checked. OSA was diagnosed when the AHI was 
greater than 5. Mild, moderate, and severe OSA were defined by 
indices of 5–14, 15–29, and >30, respectively. BP was measured 
twice either with a mercury sphygmomanometer or an aneroid 
sphygmomanometer (Welch Allyn Silver Series DS45, Ska-
neateles Falls, NY, USA), and the average value was used.
Anthropometric measurements and metabolic 
assessments 
Anthropometric measurements were performed by a skilled 
examiner. Height was defined as the length from the top of the 
head to the end of the first toe. Neck circumference (NC) was 
measured at the thyroid cartilage level with a ruler. Waist cir-
cumference (WC) was measured at the midway point between 
the inferior costal margin and the superior border of the iliac 
crest. Hip circumference (HC) was measured at the largest lat-
eral extension of the hips. 
Blood samples were collected after overnight fasting, and the 
levels of total cholesterol, triglycerides (TG), high-density lipo-
protein (HDL)-cholesterol, low-density lipoprotein (LDL)-cho-
lesterol, and blood glucose were measured.
Statistics
Independent two-sample t-tests were used for the comparison 
of continuous variables. The stepwise multivariate logistic re-
gression analysis was used to determine risk factors that were 
associated with OSA. Discrete variables were compared using 
the chi-square test. The criterion for entering or removing vari-
ables in the multivariate regression model was a p-value of 0.25. 
The variables that were initially entered in the stepwise analysis 
were chosen from the preliminary univariate analyses with 
p<0.01. Statistical analyses were performed by SPSS version 20 
(IBM Corporation, Armonk, NY, USA) and SAS version 9.2 (SAS 
Institute Inc., Cary, NC, USA). 
RESULTS
Flowchart of patients
This was a retrospective analysis of the sleep apnea registry of 
the Cardiology Department at Yonsei University. During a 3-year 
period, 948 hypertensive patients underwent PSG for the evalu-
ation of secondary HTN and/or OSA-related symptoms. Among 
these subjects, 364 patients were excluded due to incomplete 
medical records, and 109 patients were excluded due to missing 
values in anthropometric measurements, laboratory tests, PSG 
data, or sleep questionnaires. Finally, 475 patients with complete 
data were enrolled in the study for analysis (Fig. 1).
Medical history of controlled and resistant 
hypertensive patients 
The enrolled patients were identified as having controlled 
(n=410) or resistant HTN (n=65). We reviewed the anti-hyper-
tensive medications that were used by patients and categorized 
them as diuretics, angiotensin-converting enzyme inhibitors, 
angiotensin-II receptor blockers, calcium channel blockers, α- 
and β-receptor blockers, and vasodilators (Table 1). The aver-
age numbers of medications that were used by patients with 
controlled and resistant HTN were 2.01±0.98 and 4.27±0.95, re-
spectively.
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Severity of OSA in patients with controlled or resistant 
HTN
OSA, which was characterized by an AHI≥5, was diagnosed in 
73.7% (302/410) and 87.7% (57/65) of patients in the controlled 
and resistant HTN groups, respectively (Table 2, Fig. 2A). Over-
all, 359 hypertensive patients (75.6%) were diagnosed with 
OSA (Table 2, Fig. 2A). The prevalence of OSA in resistant hy-
pertensive patients was significantly higher than that in con-
trolled hypertensive patients (p=0.015) (Fig. 2A). When we 
used the AHI to categorize the severity of OSA as mild, mod-
erate, or severe, the resistant HTN group had a higher percent-
age of moderate (35.4% vs. 23.2%) and severe (26.1% vs. 19.5%) 
OSA patients, compared to the controlled HTN group (Fig. 2B 
and C). 
Anthropometric characteristics, PSG, and basal 
laboratory results in patients with controlled 
or resistant HTN 
We evaluated the differences in anthropometric, polysomno-
graphic, and basal laboratory features between controlled and 
resistant hypertensive patients (Table 3). Body weights, body 
mass index (BMI), NC, WC, and HC were significantly higher 
in the resistant HTN group, compared with the controlled 
HTN group (p<0.05). Based on the independent two-sample t-
test, the AHI was also significantly higher in the resistant HTN 
group than in the controlled HTN group (p<0.05). In addition, 
resistant hypertensive patients had significantly worse values 
for polysomnographic parameters, such as average O2 satura-
tion, lowest O2 saturation, and O2 desaturation index. No dif-
ferences in the longest duration of apnea or hypopnea and av-
erage heart rate were observed between groups. Interestingly, 
TG levels were higher in patients with resistant HTN (p=0.050); 
however, there were no significant differences in the levels of 
glucose, total cholesterol, HDL-cholesterol, and LDL-choles-
terol between groups (Table 3).
Anthropometric characteristics and basal laboratory 
results in OSA and non-OSA hypertensive patients 
To determine the common variables that are associated with 
both OSA and resistant HTN, we regrouped all hypertensive 
patients into non-OSA (n=114) and OSA (n=361) groups. The 
patients who had OSA were significantly older (55.89±12.46 
years old) than non-OSA (48.72±13.74 years old) patients 
(p<0.001). Anthropometric characteristics, such as body weight, 
BMI, NC, WC, and HC, were also significantly higher in the 
OSA group than in the non-OSA group. In addition, decreased 
HDL-cholesterol levels were observed in the OSA group (p<0.05) 
(Table 4). 
The association of resistant HTN with OSA
Using the stepwise logistic regression analysis, waist (chi-
square=28.82, p<0.001), age (chi-square=35.01, p<0.001), gen-
der (chi-square=16.02, p<0.001), and NC (chi-square=3.39, 
p=0.066) were significantly associated with OSA. However, re-
sistant HTN was not significantly associated with OSA in the 
multivariate logistic regression analysis (chi-square=1.62, 
Table 1. Review of Enrolled Patients’ Blood Pressure Medications
Controlled HTN (n=410) Resistant HTN (n=65)
Number of medications 2.01±0.98 4.27±0.95
Diuretics (%) 32 86
ACEI (%) 7 14
ARB (%) 61 77
CCB (%) 56 89
α-blocker (%) 1 29
β-blocker (%) 30 78
Vasodilator (%) 11 31
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin-II receptor 
blocker; CCB, calcium channel blocker; HTN, hypertension.
Cardiology patients who performed sleep study
(regardless of symptoms) (n=948)
Missed anthropometric measurements (n=58)
Missed laboratory test (n=20)
Missed polysomnography data or questionnares (n=31)
Incomplete medical records (n=364)
Hypertensive patients who performed sleep study (n=584)
Enrolled patients (n=475)
Fig. 1. Flowchart of patients. Hypertensive patients were asked to perform the sleep study (including polysomnography, sleep questionnaires, labora-
tory tests, and anthropometric measurements), and 475 patients with complete data were enrolled in this retrospective study.
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p=0.203) (Table 5). 
DISCUSSION
The prevalence of OSA is reported to be between 2% and 7% 
in middle-aged adult populations, but the prevalence of OSA 
without symptoms has been reported to be up to 20%.21 In pa-
tients with cardiovascular disease, the prevalence of OSA has 
been shown to be as high as 60%,22 and approximately 80% of 
resistant hypertensive patients have OSA.8,9 Although previ-
ous studies have shown that the risk for OSA is significantly 
increased in subjects with resistant HTN compared to those 
with controlled HTN,23 population studies regarding the asso-
ciation between resistant HTN and OSA are limited. Because 
resistant HTN and OSA share common risk factors, including 
age and obesity,1,24 we sought to determine whether resistant 
HTN is an independent risk factor for OSA. We also examined 
whether resistant HTN and OSA are causally related. 
First, we compared various clinical characteristics, such as 
body weight, BMI, NC, WC, and HC, between controlled and 
resistant hypertensive patients. The results showed that these 
clinical features were higher in resistant HTN patients. These 
parameters were also significantly associated with OSA in the 
entire study population (Table 4). One important risk factor for 
OSA is obesity, as 40% of obese subjects have OSA.25 Further-
more, a 10% increase in body weight contributes to a 6-fold in-
crease in the odds of developing OSA.26 Therefore, we suspect-
ed that these propensities for obesity might be responsible for 
the higher prevalence of OSA in patients with resistant HTN. 
This hypothesis was based on the fact that CPAP only modest-
ly reduces BP in OSA patients. In the open-randomized HIPAR-
CO study, which assessed the effect of CPAP in patients with re-
sistant HTN, there was a small but significant decrease in mean 
BP over a 24-hour period.27 Through a meta-analysis of 16 ran-
domized clinical trials, Bazzano, et al.28 concluded that effective 
CPAP treatment reduces BP, but its mean effect is modest at 
best. Although there are various differences in the duration of 
treatment, CPAP adherence, study design, and cohort size of 
these clinical trials, the modest effect of CPAP suggests that 
OSA may be a partial contributing factor to the pathophysio-
logical mechanism of resistant HTN development. In addi-
tion, Friedman, et al.29 have demonstrated that the association 
between OSA and resistant HTN may be due to exaggerated 
fluid volume displacement from the legs to the upper airways. 
However, this is not supported clinically, because β-blockers, 
rather than diuretics, are more effective in reducing BP in hy-
pertensive subjects with OSA.
OSA is characterized by repetitive pharyngeal narrowing dur-
ing sleep. This is due to the deposition of fat in the upper air-
Table 2. Severity of OSA Based on the AHI in Patients with Controlled or Resistant HTN 
Controlled HTN (n=410) Resistant HTN (n=65) Total (n=475)
Average AHI Number (%) Average AHI Number (%) Average AHI Number (%)
Non-OSA (0–4.9) 2.10 108 (26.3) 2.87 8 (12.3) 2.15 116 (24.4)
Mild (5–14.9) 9.55 127 (31.0) 9.17 17 (26.2) 9.50 144 (30.4)
Moderate (15–29.9) 20.94 95 (23.2) 20.67 23 (35.4) 20.88 118 (24.8)
Severe (30+) 45.63 80 (19.5) 49 17 (26.1) 46.21 97 (20.4)
Total 17.26 410 (100) 22.87 65 (100) 18.03 475 (100)
HTN, hypertension; AHI, apnea-hypopnea index; OSA, obstructive sleep apnea.
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Fig. 2. Severity of OSA in HTN. The apnea-hypopnea index (AHI) was used to determine the prevalence and severity of OSA in controlled and resis-
tant hypertensive patients. (A) The prevalence of OSA in controlled, resistant, and total hypertensive patients was compared. (B) The average AHIs of 
non-OSA, mild, moderate, and severe degrees of OSA are represented as mean±standard deviation in the controlled and resistant HTN groups. (C) 
The percentages of patients with non-OSA, mild, moderate, and severe OSA were compared between the controlled and resistant HTN groups 
(*p<0.05). OSA, obstructive sleep apnea; HTN, hypertension.
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the aggravation of OSA, and it is well established in non-obese 
patients.31 However, Jafari and Mohsenin32 showed that fluid shift 
does not significantly change the respiratory disturbance index, 
way30 and the redistribution of intravascular and interstitial flu-
id in the pharyngeal structure. The hypothesis of rostral fluid 
shift from the legs into the neck is a potential mechanism for 
Table 3. Anthropometric Characteristics, Polysomnography, and Basal Laboratory Results in Patients with Controlled or Resistant HTN
Controlled HTN (n=410) Resistant HTN (n=65) p value
Age (yrs) 54.33±12.85 53.15±14.83 0.500
Sex, male:female (percentage of male) 303:107 (73.9%) 47:18 (72.3%) 0.786
Height (cm) 166.94±8.47 167.84±7.33 0.417
Weight (kg) 73.30±11.94 79.96±16.05 <0.001
BMI (kg/m2) 26.10±3.27 28.05±4.18 <0.001
Neck circumference (cm) 38.11±3.20 39.98±3.75 <0.001
Waist circumference (cm) 93.05±8.93 99.12±9.28 <0.001
Hip circumference (cm) 100.01±7.16 103.67±8.99 0.003
ESS 7.39±4.27 7.24±4.01 0.789
Total NREM sleep duration (min) 256.99±128.54 296.52±75.92 0.001
Total REM sleep duration (min) 71.23±35.68 66.01±35.40 0.273
Percentage of NREM sleep (%) 57.89±26.92 68.69±8.50 <0.001
Percentage of REM sleep (%) 16.02±7.30 15.25±7.63 0.432
Total AHI 17.27±16.81 22.88±19.46 0.015
The longest apnea duration (sec) 29.99±20.33 27.79±16.39 0.334
The longest hypopnea duration (sec) 47.19±21.05 49.53±18.86 0.399
Average O2 saturation (%) 95.04±1.62 94.37±1.93 0.003
Lowest O2 saturation (%) 85.20±5.76 83.52±6.56 0.033
O2 desaturation index 16.05±15.89 22.57±19.04 0.003
Average HR 62.63±9.88 62.31±9.58 0.806
Glucose (mg/dL) 108.53±29.05 116.85±46.43 0.165
Cholesterol (mg/dL) 177.43±40.19 180.71±42.33 0.544
TG (mg/dL) 129.53±89.19 150.24±100.85 0.050
HDL (mg/dL) 46.64±12.03 43.91±10.30 0.084
LDL (mg/dL) 106.55±36.61 102.24±35.10 0.259
BMI, body mass index; ESS, Epworth sleepiness scale; REM sleep, rapid eye movement sleep; NREM sleep, non rapid eye movement sleep; AHI, apnea-hypop-
nea index; HR, heart rate; TG, triglyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HTN, hypertension.
Data with normal distribution are presented as mean±standard deviation.
Table 4. Univariate Logistic Regression Analysis of Risk Factors Associated with the Prevalence of OSA 
Variables Non-OSA (n=114) OSA (n=361) OR (95% CI) p value
Age (yrs) 48.72±13.74 55.89±12.46 1.044 (1.026–1.062) <0.001
Sex, male:female (percentage of male) 70:44 (60.5%) 280:81 (77.9%) 0.460 (0.293–0.722) <0.001
Height (cm) 166.44±8.31 167.25±8.33 1.012 (0.986–1.037) 0.367
Weight (kg) 70.66±12.59 75.33±12.65 1.032 (1.013–1.052) <0.001
BMI (kg/m2) 25.31±3.48 26.70±3.41 1.140 (1.063–1.222) <0.001
Neck circumference (cm) 36.97±3.44 38.82±3.19 1.194 (1.114–1.280) <0.001
Waist circumference (cm) 89.84±10.23 95.17±8.48 1.073 (1.045–1.102) <0.001
Hip circumference (cm) 98.62±6.53 101.24±7.72 1.051 (1.019–1.083) 0.002
Glucose (mg/dL) 104.62±27.92 111.77±33.78 1.009 (1.000–1.018) 0.056
TG (mg/dL) 135.31±94.76 154.29±101.50 1.002 (1.000–1.005) 0.065
HDL (mg/dL) 48.75±11.68 45.48±11.79 0.977 (0.961–0.995) 0.011
LDL (mg/dL) 108.75±37.21 105.89±35.77 0.997 (0.991–1.003) 0.259
Controlled:resistant (percentage of resistant HTN) 106:8 (7.0%) 304:57 (15.8%) 2.484 (1.148–5.378) 0.021
BMI, body mass index; TG, triglyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein; OSA, obstructive sleep apnea; HTN, hypertension; OR, odds 
ratio; CI, confidence interval.
Data with normal distribution are presented as mean±standard deviation.
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which is a sum of the AHI and respiratory effort-related arousal, 
and it does not worsen the severity of OSA.
Results from our stepwise logistic regression analyses showed 
that resistant HTN itself was not significantly associated with 
OSA, after controlling for age and indices of obesity, compared 
to total HTN patients (Table 5). Although resistant HTN was 
significantly associated with the presence of OSA in univariate 
analysis (Table 4), the association became non-significant 
when the obesity factors were adjusted by stepwise and multi-
variate analyses and controlled HTN was compensated (Table 
5). In addition, the results in Table 3 showed that resistant 
HTN had more obesity than controlled HTN. Similar to our 
finding, it has been reported that weight loss combined with 
CPAP was effective for the control of blood pressure.33 Taken to-
gether, these findings suggest that the high prevalence of OSA 
in resistant hypertensive patients is due to the sharing of com-
mon risk factors (Table 3 and 5). Furthermore, the correction of 
clinical risk factors should not be overlooked in the manage-
ment of resistant hypertensive patients. In particular, obesity 
should be emphasized for both OSA and resistant HTN. There-
fore, both weight loss and CPAP usage are necessary for BP 
control in overweight patients with concurrent resistant HTN 
and OSA. 
Another risk factor for the pathogenesis of cardiovascular 
disease, including resistant HTN, is metabolic syndrome. Im-
portantly, it is highly associated with OSA.34 Results from mul-
tivariate analyses show that the presence of OSA was signifi-
cantly associated with metabolic syndrome in all hypertensive 
groups (OR=2.529, p<0.001) (Supplementary Fig. 1, only on-
line). Although the high prevalence of metabolic syndrome 
may be due to common sharing of risk factors, such as obesity, 
OSA itself can enhance insulin resistance by increasing sym-
pathetic nervous system activation and elevating systemic in-
flammation.34 This is supported by the fact that CPAP usage is 
associated with an improvement in lipid profiles, glycosylated 
hemoglobin levels, and BP.35
Our study has several limitations. First, this was a retrospec-
tive analysis of registry data with cross-sectional analysis. Sec-
ond, we did not have full data regarding the etiologies of sec-
ondary HTN in the resistant HTN group. Third, portable PSG 
was used instead of fully attended in-laboratory PSG, which is 
typically used in the diagnosis of OSA. However, our device is a 
type 2 portable monitor with EEG channels, which enables the 
AHI to be accurately calculated, and this was manually scored 
by sleep technologists and validated by a sleep expert. Portable 
PSG is effective and may be used as an alternative to in-labo-
ratory PSG, especially in patients with a high clinical probabil-
ity of OSA.36-38 Fourth, we did not exclude subjects with white-
coat hypertension. Lastly, as we utilized hospital-based registry 
data, the results from the study cannot be generalized to the 
general population. Nevertheless, the ability to analyze the as-
sociation between resistant HTN and OSA in a relatively large 
registry is a merit of this study. 
We evaluated various clinical and polysomnographic charac-
teristics in controlled and resistant hypertensive patients who 
were suspected to have OSA, and found that the prevalence of 
OSA was higher and more severe in patients with resistant 
HTN than those with controlled HTN. Our results from univar-
iate and stepwise logistic analyses showed that resistant HTN 
was not an independent risk factor for OSA, and that the high 
prevalence of OSA in resistant HTN was due to the sharing of 
common risk factors for both conditions. 
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